{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:41:25Z","timestamp":1788198085894,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current treatment pathways for moderate-to-severe psoriasis in the UK and the Republic of Ireland direct initiation of targeted biologic immunomodulators when conventional systemic drugs are ineffective or not tolerated. Starting biologics early in the treatment pathway may modify disease course and improve short- and long-term outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the effectiveness and risk of incident comorbid conditions over 5\u2005years when initiating a biologic as the first systemic treatment vs. the current standard of care, in which the patients started with a\u00a0conventional non-biologic systemic therapy with possible subsequent switch to biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study applied the target trial emulation framework using data from the British Association of Dermatologists Biologics and Immunomodulators Register. Adults (aged \u2265 18\u2005years) with moderate-to-severe psoriasis [baseline Psoriasis Area and Severity Index (PASI) \u2265 10] and no prior systemic therapy were included. Five-year trajectories of PASI and Dermatology Life Quality Index (DLQI) were modelled using mixed-effects repeated-measures models. The probability of complete skin clearance (PASI 0) and the risk of developing long-term comorbidities (cardiovascular, hepatic, neoplastic, metabolic, mental health or musculoskeletal disorders, and incident psoriatic arthritis) were estimated using marginal structural models with stabilized inverse probability weighting to adjust for baseline and time-varying confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 3702 patients: 3368 followed the current standard of care and 334 initiated a biologic as first-line systemic therapy. At 5\u2005years, the modelled mean PASI was 4.7 [95% confidence interval (CI) 4.0\u20135.4] for standard of care and 2.0 (95% CI 1.2\u20132.7) for biologic initiators; DLQI were 5.6 (95% CI 4.2\u20137.0) and 3.5 (95% CI 1.3\u20135.7), respectively. The cumulative rate of achieving PASI 0 was 32.2 vs. 58.6%, with a higher likelihood of PASI 0 for biologic initiators [hazard ratio (HR) 2.85, 95% CI 2.34\u20133.47]. The cumulative risk of chronic comorbidities was lower among biologic initiators (47.5 vs. 54.3%; HR 0.72, 95% CI 0.58\u20130.89), with lower risks of mental health (HR 0.64, 95% CI 0.44\u20130.94) and hepatic (HR 0.54, 95% CI 0.38\u20130.76) disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initiating biologics as the first systemic therapy was associated with better clinical outcomes compared with standard stepwise approaches. Our results support reconsideration of existing pathways to allow earlier use of biologics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljag098","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:15:35Z","timestamp":1773404135000},"page":"58-67","source":"Crossref","is-referenced-by-count":4,"title":["Using biologic therapies as first-line systemic treatment for psoriasis: a cohort study following the target trial emulation framework using data from the British Association of Dermatologists Biologics and Immunomodulators Register"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-9093","authenticated-orcid":false,"given":"Duc Binh","family":"Phan","sequence":"first","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust and Division of Musculoskeletal and Dermatological Sciences, University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-0699","authenticated-orcid":false,"given":"Philip","family":"Laws","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Leeds , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H","family":"Smith","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, King\u2019s College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E M","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust and Division of Musculoskeletal and Dermatological Sciences, University of Manchester , Manchester ,","place":["UK"]},{"name":"Department of Dermatology, King\u2019s College Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s University Hospital and Charles Institute of Dermatology, University College Dublin , Dublin ,","place":["Republic of Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9587-9430","authenticated-orcid":false,"given":"Olivia","family":"Hughes","sequence":"additional","affiliation":[{"name":"School of Psychology, Cardiff University , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9339-7374","authenticated-orcid":false,"given":"Gabriel","family":"Rogers","sequence":"additional","affiliation":[{"name":"Manchester Centre for Health Economics, University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oras A","family":"Alabas","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust and Division of Musculoskeletal and Dermatological Sciences, University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[{"name":"Versus Arthritis Epidemiology Unit, University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust and Division of Musculoskeletal and Dermatological Sciences, University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z N","family":"Yiu","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust and Division of Musculoskeletal and Dermatological Sciences, University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"2026062312163848300_ljag098-B1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2026062312163848300_ljag098-B2","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026062312163848300_ljag098-B3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjd.15021","article-title":"Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study","volume":"176","author":"Springate","year":"2017","journal-title":"Br J Dermatol"},{"key":"2026062312163848300_ljag098-B4","author":"NICE"},{"key":"2026062312163848300_ljag098-B5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.wndm.2013.06.001","article-title":"Cumulative Life Course Impairment (CLCI): a new concept to characterize persistent patient burden in chronic wounds","volume":"1","author":"Augustin","year":"2013","journal-title":"Wound Med"},{"issue":"Suppl. 1","key":"2026062312163848300_ljag098-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2011.10280.x","article-title":"Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course","volume":"164","author":"Warren","year":"2011","journal-title":"Br J Dermatol"},{"key":"2026062312163848300_ljag098-B7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","article-title":"Psoriasis: is the impairment to a patient\u2019s life cumulative?","volume":"24","author":"Kimball","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026062312163848300_ljag098-B8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bjd.18209","article-title":"The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership","volume":"181","author":"Majeed-Ariss","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026062312163848300_ljag098-B9","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial - the TARGET statement","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"key":"2026062312163848300_ljag098-B10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2133.2012.10835.x","article-title":"The British Association of Dermatologists\u2019 Biologic Interventions Register (BADBIR): design, methodology and objectives","volume":"166","author":"Burden","year":"2012","journal-title":"Br J Dermatol"},{"key":"2026062312163848300_ljag098-B11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/1536867X0400400403","article-title":"Controlling for time-dependent confounding using marginal structural models","volume":"4","author":"Fewell","year":"2004","journal-title":"Stata J"},{"key":"2026062312163848300_ljag098-B12","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"2026062312163848300_ljag098-B13","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026062312163848300_ljag098-B14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1541-0420.2010.01449.x","article-title":"Double inverse-weighted estimation of cumulative treatment effects under nonproportional hazards and dependent censoring","volume":"67","author":"Schaubel","year":"2011","journal-title":"Biometrics"},{"key":"2026062312163848300_ljag098-B15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jvc2.63","article-title":"Early intervention and disease memory in psoriasis: a literature review","volume":"1","author":"Ben Abdallah","year":"2022","journal-title":"JEADV Clin Pract"},{"key":"2026062312163848300_ljag098-B16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/bjd\/ljaf403","article-title":"Breaking the cycle of psoriasis: the role for early intervention","volume":"194","author":"Graier","year":"2026","journal-title":"Br J Dermatol"},{"key":"2026062312163848300_ljag098-B17","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2026062312163848300_ljag098-B18","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jaad.2021.02.019","article-title":"Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study","volume":"84","author":"Gelfand","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"2026062312163848300_ljag098-B19","first-page":"Cd011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026062312163848300_ljag098-B20","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/cells13221906","article-title":"Inflammation: the cause of all diseases","volume":"13","author":"Chavda","year":"2024","journal-title":"Cells"},{"key":"2026062312163848300_ljag098-B21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2026062312163848300_ljag098-B22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2026062312163848300_ljag098-B23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"2026062312163848300_ljag098-B24","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026062312163848300_ljag098-B25","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1080\/13696998.2024.2379212","article-title":"Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective","volume":"27","author":"Clarke","year":"2024","journal-title":"J Med Econ"},{"key":"2026062312163848300_ljag098-B26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1198\/016214501753168154","article-title":"Marginal structural models to estimate the joint causal effect of nonrandomized treatments","volume":"96","author":"Hern\u00e1n","year":"2001","journal-title":"J Am Stat Assoc"},{"key":"2026062312163848300_ljag098-B27","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"2026062312163848300_ljag098-B28","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag098\/67363694\/ljag098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/1\/58\/67363694\/ljag098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/1\/58\/67363694\/ljag098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:16:48Z","timestamp":1782231408000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/195\/1\/58\/8524483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag098","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,16]]}}}